Cargando…
Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
Background: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide–formoterol (DuoResp) Spiromax; flow rates through empty versions...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601554/ https://www.ncbi.nlm.nih.gov/pubmed/26352860 http://dx.doi.org/10.1089/jamp.2015.1216 |
_version_ | 1782394567095484416 |
---|---|
author | Canonica, Giorgio Walter Arp, Jan Keegstra, Johan René Chrystyn, Henry |
author_facet | Canonica, Giorgio Walter Arp, Jan Keegstra, Johan René Chrystyn, Henry |
author_sort | Canonica, Giorgio Walter |
collection | PubMed |
description | Background: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide–formoterol (DuoResp) Spiromax; flow rates through empty versions of the Spiromax and Turbuhaler inhaler) of importance to patients with asthma or COPD. Methods: Dose-delivery studies were performed using low-, middle-, and high-strength DuoResp Spiromax. Dose consistency was assessed over inhaler life. Total emitted doses (TEDs) were measured at various flow rates, after exposure to high and low temperature or humidity, at different inhaler orientations, and after dropping the inhaler. The criterion for evaluating dose uniformity was whether mean TEDs were within the product specification limits. In separate studies, flow rates were measured after training, using the patient information leaflets, and again after enhanced training as part of a randomized, open-label, cross-over study. Results: Mean values for both budesonide and formoterol were within 85%–115% of the label claim for each strength of DuoResp Spiromax for initial dose uniformity and for the other investigated conditions (temperature, humidity, orientation, dropping, knocking), with the exception of approximately an 80% increase in first dose after dropping the inhaler (subsequent doses not affected). In the flow rate patient study, two patients' inhalations with Spiromax and six with Turbuhaler were <30 L/min. The majority of asthma patients [91% (Spiromax) versus 82% (Turbuhaler)] achieved the preferred flow rate of >60 L/min. Conclusions: DuoResp Spiromax consistently meets dose uniformity criteria, under controlled laboratory conditions and with variations intended to mimic real-world use. Following enhanced training, all patients in the flow study were able to achieve the minimal inspiratory flow rate of >30 L/min, which is required for effective treatment. |
format | Online Article Text |
id | pubmed-4601554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Mary Ann Liebert, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-46015542015-10-20 Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions Canonica, Giorgio Walter Arp, Jan Keegstra, Johan René Chrystyn, Henry J Aerosol Med Pulm Drug Deliv Original Research Background: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide–formoterol (DuoResp) Spiromax; flow rates through empty versions of the Spiromax and Turbuhaler inhaler) of importance to patients with asthma or COPD. Methods: Dose-delivery studies were performed using low-, middle-, and high-strength DuoResp Spiromax. Dose consistency was assessed over inhaler life. Total emitted doses (TEDs) were measured at various flow rates, after exposure to high and low temperature or humidity, at different inhaler orientations, and after dropping the inhaler. The criterion for evaluating dose uniformity was whether mean TEDs were within the product specification limits. In separate studies, flow rates were measured after training, using the patient information leaflets, and again after enhanced training as part of a randomized, open-label, cross-over study. Results: Mean values for both budesonide and formoterol were within 85%–115% of the label claim for each strength of DuoResp Spiromax for initial dose uniformity and for the other investigated conditions (temperature, humidity, orientation, dropping, knocking), with the exception of approximately an 80% increase in first dose after dropping the inhaler (subsequent doses not affected). In the flow rate patient study, two patients' inhalations with Spiromax and six with Turbuhaler were <30 L/min. The majority of asthma patients [91% (Spiromax) versus 82% (Turbuhaler)] achieved the preferred flow rate of >60 L/min. Conclusions: DuoResp Spiromax consistently meets dose uniformity criteria, under controlled laboratory conditions and with variations intended to mimic real-world use. Following enhanced training, all patients in the flow study were able to achieve the minimal inspiratory flow rate of >30 L/min, which is required for effective treatment. Mary Ann Liebert, Inc. 2015-10-01 /pmc/articles/PMC4601554/ /pubmed/26352860 http://dx.doi.org/10.1089/jamp.2015.1216 Text en © The Author(s) 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Canonica, Giorgio Walter Arp, Jan Keegstra, Johan René Chrystyn, Henry Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions |
title | Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions |
title_full | Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions |
title_fullStr | Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions |
title_full_unstemmed | Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions |
title_short | Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions |
title_sort | spiromax, a new dry powder inhaler: dose consistency under simulated real-world conditions |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601554/ https://www.ncbi.nlm.nih.gov/pubmed/26352860 http://dx.doi.org/10.1089/jamp.2015.1216 |
work_keys_str_mv | AT canonicagiorgiowalter spiromaxanewdrypowderinhalerdoseconsistencyundersimulatedrealworldconditions AT arpjan spiromaxanewdrypowderinhalerdoseconsistencyundersimulatedrealworldconditions AT keegstrajohanrene spiromaxanewdrypowderinhalerdoseconsistencyundersimulatedrealworldconditions AT chrystynhenry spiromaxanewdrypowderinhalerdoseconsistencyundersimulatedrealworldconditions |